Journal profile · Medicine-Immunology and Allergy
Clinical Immunology Communications
ISSN 2772-6134 · Elsevier · United States
Clinical Immunology Communications: diamond open access (no APC); no APC; review about 47 days (submission to acceptance, publisher); 25 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Clinical Immunology Communications is published by Elsevier. By OpenAlex counts of its recent articles, its largest topics are Immunodeficiency and Autoimmune Disorders, SARS-CoV-2 and COVID-19 Research and COVID-19 Clinical Research Studies, together about 38% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Clinical Immunology Communications is a new online only, open-access journal that publishes high-quality, peer-reviewed contributions in the evolving areas of clinical immunology.The journal considers submissions transferred from Clinical Immunology, as well as direct submissions on basic, translational and clinical studies in vitro and in vivo in animal models and in humans, to advance the understanding of cellular, biochemical and molecular aspects of clinical immunology for broad audiences.The ultimate goal of Clinical Immunology Communications is to provide readers with new information on a wide range of clinical immunology subjects including: (1) autoimmune diseases; (2) hypersensitivity and allergy; (3) tumor immunology; (4) immunodeficiencies; (5) immunity to infection including HIV; (6) vaccines; (7) transplantation; (8) new immunological methods and techniques. The types of manuscripts considered for publication will include: (1) original articles; (2) brief communications; (3) reviews; (4) case reports or case cohorts; (5) editorials (by invitation only); (6) guidelines (written by academic authorities and focusing on clinical diagnosis and/or treatment, or use of methodologies in clinical immunology).
From the journal's Aims & Scope
Research area (LetPub): Medicine-Immunology and Allergy
Editor-in-chief Antonio La CavaPublisher website
Editorial board by country: 7 in mainland China (about 14%); most named United States 23, Mainland China 7, Japan 6, United Kingdom 3, Italy 3 (50 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immunodeficiency and Autoimmune DisordersImmunology and Microbiology14.4%
- SARS-CoV-2 and COVID-19 ResearchMedicine13.1%
- COVID-19 Clinical Research StudiesMedicine10.6%
- T-cell and B-cell ImmunologyImmunology and Microbiology9.3%
- Autoimmune and Inflammatory Disorders ResearchMedicine5.5%
- Cancer Immunotherapy and BiomarkersMedicine3.8%
- Vasculitis and related conditionsMedicine3.4%
- Immune responses and vaccinationsImmunology and Microbiology3.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Immunology and Allergy | Q4 | 184/234 | 21st |
| Immunology | Q4 | 198/243 | 18th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 1.9LetPub ·
- CiteScore (publisher)
- 1.9Publisher website ·
- SJR 2026-06
- 0.29LetPub ·
- SNIP 2026-06
- 0.32LetPub ·
- h-index
- 10OpenAlex ·
- i10-index
- 13OpenAlex ·
- 2-year mean citedness
- 1.53OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 149 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 31 | 31 | 128 |
| 2025 | 25 | 25 | 94 |
| 2024 | 20 | 20 | 84 |
| 2023 | 28 | 28 | 84 |
| 2022 | 32 | 32 | 34 |
| 2021 | 13 | 13 | 5 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Publisher-reported review time from the journal's website
47 dayssubmission to acceptance · community reports about 10 weeks
The publisher's own definition applies; dates from this journal's articles in the last 24 months are not available yet, so the publisher's figure is used.
Figures by source
- Average review time (community reports)
- about 10 weeksLetPub ·
- Submission to first decision
- 1 daysPublisher website ·
- First decision after review
- 24 daysPublisher website ·
- Submission to acceptance
- 47 daysPublisher website ·
- Acceptance to publication
- 1 daysPublisher website ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 1,860 / EUR 1,740 / GBP 1,490 / JPY 230,700 | — | — | |
| LetPub | USD 1,750 | Yes | — | |
| Publisher website | USD 2,560 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Numbered, in order of citation
- Highlights
- Optional
- Graphical abstract
- Optional
Article types accepted5
- brief communicationsThe types of manuscripts considered for publication will include: (1) original articles; (2) brief communications; (3) reviews; (4) case reports or case cohorts…Length not stated
- case reports or case cohortsThe types of manuscripts considered for publication will include: (1) original articles; (2) brief communications; (3) reviews; (4) case reports or case cohorts…Length not stated
- editorials (by invitation only)The types of manuscripts considered for publication will include: (1) original articles; (2) brief communications; (3) reviews; (4) case reports or case cohorts…Length not stated
- original articlesThe types of manuscripts considered for publication will include: (1) original articles; (2) brief communications; (3) reviews; (4) case reports or case cohorts…Length not stated
- reviewsThe types of manuscripts considered for publication will include: (1) original articles; (2) brief communications; (3) reviews; (4) case reports or case cohorts…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- United States
- Language
- English
- ISSN
- 2772-6134
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Clinical Immunology Communications
How long does peer review take at Clinical Immunology Communications?
The publisher reports about 47 days (submission to acceptance); authors report an average review time of about 10 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Clinical Immunology Communications?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Numbered, in order of citation; Highlights: Optional; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Clinical Immunology Communications based?
Of the 50 board members whose country the journal's board page names, 7 (about 14%) are in mainland China; the countries named most often are United States (23), Mainland China (7) and Japan (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical Immunology Communications?
According to LetPub and DOAJ records, Clinical Immunology Communications is indexed in Scopus and DOAJ.
Is Clinical Immunology Communications open access, and what is the APC?
Clinical Immunology Communications is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .